[Update (8.2023): SBIR/STTR funding total - $1.9M, Venture funding total - $2.85M] Working men and women lift every day. They do it in warehouses and on production lines. In offices and combat zones. Every day, they lift the economy worldwide. Whether it’s the day-to-day grind or responding to a crisis, their strength supports us all. And they deserve gear that sustains their strength, for work and for life. That makes their job safer. The HeroWear Apex means that their weight is over. The world’s first exosuit for all, built from the ground up for both men and women, the Apex is a back-assist exosuit that uses a proprietary band-based mechanism to reduce strain on the back without getting in the way.
A vast majority of drugs and biologics fail to enter the brain for treatment of brain cancers and neurological diseases. Our discovery yielded key insights into how the immune system naturally overcomes the blood brain barrier to fight infections. We leverage this insight to enable safe and transient drug access to the CNS using a simple intranasal peptide delivery approach.
The human immune system participates in complex interactions with virtually all other systems in the body. In particular, the B-cell component of the adaptive immune response plays a role in various disease settings, including infectious disease, cancer, autoimmunity, cardiovascular, hematologic, neurologic diseases, and others. In addition, antibodies (a product of B cells) are effectively used in diagnostics, therapy, and prevention. To address these significant challenges with current technologies for B cell characterization and antibody discovery, we recently developed a novel technology that, for a given sample, enables the mapping of antibody sequence to antigen specificity from a single high-throughput experiment for a large number of antigens and B cells at a time.
Trivie is a SaaS company that offers an on-demand gamification platform to improve knowledge retention for employees. The platform employs retrieval practice, micro-learning, and adaptive learning that help companies considerably reduce training costs, increase sales, and provide better customer service.
The scientific community is continuously trying to improve their understanding of genetic mechanisms in biological systems and finding biomarkers for diagnosis, prognosis and treatment. With growing accessibility, still, only the minority of investigators in the life and medical sciences has the means to analyze and leverage this enormous treasure of data. Bioada is an integrated, easy to use and interactive genomics data analysis platform for the broader community of life scientists.
Bone-Rad Therapeutics, Inc. is a Delaware corporation whose objective is to develop and market Spine-Rad (TM) Brachytherapy Bone Cement as an innovative, improved, and cost-effective treatment paradigm for the management of cancer tumors in the spine which affect over 230,000 patients per year in the U.S. and a similar number in the E.U. Four patents covering this technology have been issued and exclusively licensed to Bone-Rad Therapeutics. An additional patent is pending. Developed at The University of California Irvine, Spine-Rad Cement delivers internally-targeted radiation therapy directly to the tumor as it simultaneously treats existing or impending vertebral fractures, restoring strength to the bone. Administered in a single procedure, Spine-Rad Cement will eliminate the 10-20 hospital visits typically needed for external beam radiation therapy (EBRT) as well as the significant side effects of EBRT.
A Novel Chemical Approach to Target p53 Mutation in Human Cancer. There is currently no treatment that specifically targets p53 mutation, the most common genetic abnormality associated with cancer. Loss of p53 tumor suppressor function provides cells with a proliferative advantage but renders them susceptible to metabolic stress. We have developed potent and selective inhibitors for PIP4K2A and PIP4K2B that regulate cell metabolism and are essential for the growth of p53-deficient tumor.
The prevalence of chronic pain is currently on the rise, however, there are few effective and accessible cognitive-behavioral interventions that are widely available to the population experiencing chronic pain. Limited healthcare system capabilities and high treatment costs prevent many patients from receiving or even seeking non-pharmaceutical care. Therefore, there is a need for a more accessible, affordable, and efficacious technology that will allow individuals with acute or chronic pain to track and manage their pain symptoms and triggers. The SOMA Pain Manager is a smartphone application that allows acute and chronic pain patients to track and predict pain. Further, a digital therapeutic program is currently being integrated into the application that will deliver cognitive-behavioral interventions. Overall, the SOMA app provides an easy and accessible option for individuals seeking to manage and treat their pain symptoms.
Individual genomic testing to provide personalized medicine to improve behavioral health. Focusing on PTSD, they provide insight for those living with the condition and promote further research and discovery.
(10.2022 Update -Princeton NuEnergy, Inc. ("PNE"), an emerging growth company primarily engaged in the regeneration of lithium-ion battery ("LIB") material, announced it successfully closed a seed funding round at $7M in Q4 2021. The round was led by Wistron Corporation (TPE: 3231), a Fortune Global 500 member and an industry leader in electronics recycling services. Other investors in the round include Shell Ventures, Greenland Technologies (NASDAQ: GTECH), CleanTech Open, AIBasis Fund, WorldQuant Ventures, and the angel round investors. Princeton NuEnergy ("PNE") is an innovative clean-tech startup company spun out from Princeton University in 2019 focused on the direct recycling of lithium-ion batteries from electric vehicles and consumer electronics. Opened its Lithium-Ion Battery (LIB) Direct Recycling 500-ton pilot production line with Wistron GreenTech. )
As part of a portfolio of COVID-19 inspired innovations aimed at advancing RNA vaccines and tools, Stanford researchers have developed a secured, invite-only version of their popular Eterna platform for designing mRNA vaccines, called Inceptive. Inceptive is an online application that integrates RNA folding algorithms, a video game interface, and associated computational methods to revolutionize vaccine design and RNA structure prediction. The new, secured version of the platform is able to host selected participants to work in a confidential manner on problems such as designing improved mRNA vaccines that can be translated to clinical trials by industry partners and other collaborators. The data and designs generated by Inceptive users may be used to develop improved mRNA vaccines immediately for the COVID-19 pandemic.
Real time capture of microscope video that is digitized, formatted and stored for AI and ML based use to enhance patient diagnosis.
[Update (8.2023): The company raised $6 million through a combination of Seed 3, and Seed 4 funding on February 14, 2023] Integrating proprietary technologies, the GutLab, “smart bathroom” technology for continuous patient microbiome tracking & MetaBiome, a cloud-based bioinformatics platform. Novel tools to continuously track, analyze, and store individual microbiome profiles, providing vastly more data than, and at a fraction of the cost of, current practice. Creating the GutLab, a novel “smart bathroom” technology for continuous, at-home microbiome tracking & MetaBiome, a cloud-based bioinformatics platform. This platform is a generational leap over existing measurement tools: (1) much cheaper and more scalable, (2) produces & analyze dense time-series data, unlocking an entire dimension of never-before-accessible biomarkers, and (3) has far higher accuracy & precision, ensuring all data generated can be stored in a single, standardized database – a first for the microbiome field.
The company boasts the world’s most advanced molecular AI platform that combines 3D structure-aware deep neural networks, new molecular simulation methods, and a massively scalable molecular generation engine.
Talent acquisition agency that utilizes artificial intelligence to create pre-employment assessments for effective skill-to-work matching. Glider AI provides customers with the Glider AI suite tools that hires qualified talent on technical and non-technical levels, combating hiring deception during the interview process. They are most known for their assessment software. This is an AI program that evaluates tech and non-tech skills, and measures behavioral and cognitive characteristics in applicants.
OT Bio aims to apply our patented intranasal oxytocin therapy to treat sleep apnea and protect patients from associated heart disease. The scientific leaders have complementary bench and clinical expertise that has enabled both understanding of oxytocin's mechanisms in the brain and human studies showing improved respiratory and cardiac functions.
Comfortable cloth nanotechnology undergarment captures from a patient at home more than 85 medical biomarkers that can be monitored by medical staff remotely. (University of Arkansas)
[Update (8.2023) SBIR/STTR funding total: $281k] Pulmera enables x-ray visualization of the tracheobronchial tree to aid physicians in guiding endoscopic tools in the pulmonary tract. Early diagnosis and treatment are vital for improving lung cancer survival rates, and tissue biopsy is necessary for diagnosis. However, performing a lung biopsy is difficult due to the complexity of the highly branched airways of the lung, making it difficult to access and obtain the tissue and the procedure can pose a risk to the patient. Electromagnetic navigation bronchoscopy (ENB) is the safest way to obtain a biopsy but diagnostic success is limited by poor real time visualization of significant portions of the lung. Should the biopsy procedure be unsuccessful, patients may then need to have the tissue surgically removed. In a high number of these cases, the nodules are found to be benign. Pulmera will greatly improve the ability to obtain a diagnosis for the patient using ENB.
[Update (8.2023): Raised seed investment from CH Innovations & Catalytic Impact Foundation & won a $500K grant from Bill & Melinda Gates Foundation in July 2022] THDG3 represents a novel, patent protected omega-3 diglyceride emulsion developed by Dr. Deckelbaum’s laboratory at Columbia University. Acute injection of THDG3 emulsion following stroke leads to a marked reduction in brain tissue death (up to 90%, demonstrated in 6 rodent models), with associated preservation and recovery of both short and long term neurofunctional outcomes. Due to the high risk profile and short window of administration, less than 8% of stroke patients receive treatment with t-PA, the current standard of treatment for stroke. DeckTherapeutics is currently developing THDG3 emulsion as a drug candidate for standard emergency treatment for stroke, a global unmet need, with phase 2a trials planned in 2021.
[Update (8.2023): SBIR/STTR funding total - $250k, Venture funding total - $8.65M, Yale Innovation prize - $2.5M] ProteoWise was founded by a seasoned team of scientists from the Strittmatter Laboratory at Yale University which has a history of commercialization of innovations emerging from the lab. ProteoWise aims to unlock the protein world. Its technology will disrupt the protein analysis industry by enabling researchers to move beyond the current Western Blot standard and into easy, high-throughput bench-top proteomics.
Addressing vital nutrient deficiencies, which are surprisingly prevalent and may lead to severe health issues, VitaScan provides rapid, accurate, and affordable testing for vitamins and micronutrients. With our first product, IronScan, we focus on swift identification of iron deficiency, affecting one-third of the global population and causing numerous health complications. Now, VitaScan's portable system allows for not only hospital avoidance but also facilitates convenient testing at a physician's office, clinic, or even at home.
[Update (8.2023): SBIR/STTR funding total - $2.17M] AnelleO is harnessing the advancements in the speed and scale of 3D printing technology for novel solutions in Women’s Health. AnelleO’s Intravaginal Rings (IVRs) offer a unique platform for sustained delivery of therapeutics – a non-invasive, self-administered and retrievable platform that can deliver drugs over a period of weeks or months. AnelleO is a medical device company that is developing a 3D printed intravaginal ring that can be used as a platform for treating a wide range of women's health conditions. Their first product, AnelleO PRO involves the only single administration of progesterone for infertility. Their technology enables controlled drug-release kinetics with up to 100% drug release, as well as rapid manufacturing and custom sizing. The manufacturing method allows for formulation of biologics and drug combinations not possible with traditional technologies.
Familial adenomatous polyposis (FAP) is a hereditary disease that affects ~50,000 families in the United States and causes the development of hundreds to thousands of adenomas in the rectum and colon. When left untreated, 100% of FAP patients develop colorectal cancer by the age of 45. Although small molecules and monoclonal antibodies targeting mTOR and IL-23 are be tested to treat FAP, these approaches are not specific to polyps and therefore cause a variety of unintended side-effects. Additionally, although genetics studies have identified variants in the APC gene as the causal mutation for FAP, gene therapy technologies need to be optimized to achieve the precision and efficacy necessary to serve as a viable therapeutic option for FAP. This technology is a monoclonal antibody targeting the Annexin A1 (ANXA1) protein complex that may be useful in treating FAP and other cancers related to ANXA1 activity.
Genome-wide association studies (GWAS) have identified thousands of noncoding variants associated with human traits and diseases. However, translating these variants into therapies continues to be a significant challenge. Alpaca Genomics has constructed a multi-tissue atlas of human 3′ UTR alternative polyadenylation (APA) quantitative trait loci (3′aQTLs), connecting thousands of noncoding GWAS variants with the APA of target genes, identified in 49 tissues isolated from 838 individuals (sourced from the Genotype-Tissue Expression Project). Alpaca Genomics is using 3’aQTLs to discover novel APA-linked susceptibility for many human diseases, such as diabetes, prostate cancer, coronary artery disease (CAD), Alzheimer’s Disease (AD), Parkinson's disease, and Amyotrophic lateral sclerosis (ALS).
GW researchers developed a cell therapy manufacturing platform that avoids genetic engineering and activates immune cells against multiple, patient-specific target antigens simultaneously. A sample of a patient’s cancer cells obtained by surgery or biopsy is treated with photothermal therapy (PTT) in vitro, delivered by Prussian blue nanoparticles (PBNPs) at an immunogenic thermal dose. Immune cells (e.g. T cells, NK cells) from the patient are then exposed to the PBNP-PTT-treated cancer cells in vitro to activate them against multiple patient-specific, tumor antigens. The activated immune cells are then re-infused to the patient. Preliminary ex vivo data and studies in xenograft animal models show superior specificity of T cells generated through this novel immuno-engineered platform against glioblastoma, over T cells generated through traditional methods.
Immuno-Modulators of Alzheimer’s Disease (I.M.A.D.) was founded by Dr. Elizabeth Bradshaw and Dr. Wassim Elyaman from Columbia University’s Department of Neurology. The team is pioneering genetically-driven strategies to treat Alzheimer’s disease by directly targeting susceptibility genes in the CNS innate immune cells, called microglia. Their lead program is a preclinical non-antibody biologic which has been shown to target the CD33 genetic susceptibility signaling pathway in human microglia and clear β-amyloid from the brain of treated mice.
Over 95% of rare disease have no treatment or cure: there are over 7,000 known rare diseases collectively affectiting 30 million Americans. Many of these disease are genetic disorders, in which there can be considerable genetic variation between patients. Current drug development pipeline does not cater to rare mutations, as drug development often takes more than 10 years and over $2B to get a drug to market, making the small patient populations inhibiting. Even if a therapy is developed, genetic variation of the disease means not all patients in the already-small patient population may be able to be treated, limiting their impact and incentive to develop these therapies.
[Update (8.2023): The company raised $3.5 million of seed funding from Industrial Technology Investment, StartX US and Wallace H. Coulter Foundation in August 2022.] PETcoil enables healthcare providers to offer PET/MRI scans with better imaging quality for a fraction of the cost compared to existing solutions. Commercial integrated PET/MRI scanners cost ~$6M + ~$2M for required room renovations, an unaffordable cost for many institutions. PETcoil's patented portable PET insert can be placed into any existing MRI scanner, enabling it to perform simultaneous PET/MRI at 1/8th of the cost compared to integrated systems. A proof-of-concept radiofrequency (RF)-penetrable PET insert has been developed and successfully tested, supported by grants from the NIH, Stanford Bio-X & Biodesign programs, and the Coulter Foundation.
Stradefy Biosciences is developing innovative bioadhesive nanoparticles (BNPs) to deliver therapeutic agents to target tissues at maximally effective doses while reducing systemic toxicities. The Company licensed from Yale technology from the laboratories of Professors Mark Saltzman and Dr. Michael Girardi with high value applications in oncology, autoimmune diseases, and other indications. ESV’s Venture Partner, Brian Dixon, is CEO. Elm Street Ventures led the Peritoneal carcinomatosis is a late stage manifestation of colon and ovarian cancer with a poor prognosis. Intraperitoneal (IP) chemotherapy is effective, but current methods lead to toxicity, which is not easily tolerated by patients. We propose a new approach, in which the chemotherapy drug is encapsulated in bioadhesive nanoparticles (BNPs) that can be delivered locally by established IP infusion methods. These BNPs are retained for many days in the IP space, and slowly release chemotherapy drugs, maximizing effectiveness, while minimizing toxicity.
Drug discovery and development is complicated, time-consuming and costly. Immunai’s computational approach and experimental apparatus is focused on understanding core pathways and mechanisms within each immune cell compartment, and the intersection of these compartments to comprehensively examine disease etiology, and how to reverse it. MIT Startup Exchange / Harvard
[Update (8.2023) SBIR/STTR funding total: $405k] Bacchus Therapeutics is a biotech company that exploits cancer’s hypermetabolic state by targeting specific cancer metabolic pathways. The aberrant expression of MYC is virtually unmatched, making MYC one of the most frequently deregulated oncogenes in human tumors, including, liver, kidney, CNS, hematopoietic, breast, prostate, lung and GI tumors. Human studies and animal models have established that dysregulation of MYC underlies the pathogenesis and aggressiveness of numerous cancers. Our founders, Drs. Gouw and Felsher, discovered that MYC regulates the aberrant lipid metabolism of tumors and that inactivation of key lipid enzymes results in regression of tumors. (Update: After receiving the IGNITE program grant in 2021, Bacchus opened a lab at one of the shared wet benches in the Prince William County Accelerator in early 2022.)
[Update (8.2023): Venture funding total - $750k] Stroke is an incredibly pervasive problem that directly affects one quarter of the world’s population. Unfortunately, many of these people are told they will never regain functional use of their arm or hand. With Reach, they will. One of our patients was able to cut food with a fork and knife and feed herself for the first time in 9 years since having her stroke. In contrast to existing assistive tools such as functional electrical stimulation, Reach’s device allows the user full control over complex and naturalistic movements. Advantages of the technology: • Assists movements in all upper limb joints • Restores naturalistic and voluntary movements • Immediate improvements • Assists users in performing tasks of daily living • Eligible for chronic stroke patients even years after their stroke • Uses standard implant device and surgical procedure • Does not require donning and doffing bulky equipment
[Update (8.2023): Venture funding total - $3.38M] My Gene Counsel has created scalable, digital technology that pairs specific genetic test results with accurate, continuously updating information for clinicians and consumers. By helping patients and doctors become aware of the implications of genetic testing results, My Gene Counsel can help improve patients' lives and avoid unnecessary risky medical procedures.
Udacity’s proven playbook is globally scalable, addressing the widespread digital talent shortages that impact growth, productivity, and innovation. We collaborate with enterprises and highly motivated individuals to design a tailored talent transformation journey enabled by our Digital Competency Platform. Our exclusive content is co-created and continually refined with industry leaders. Each Udacity program is deeply focused—eliminating guesswork in selecting the right course. Projects go far beyond step-by-step guides, cultivating the critical thinking required for workplace relevance. Expert mentors unblock learning with personalized support, and verify complete mastery of competencies.
The shortage of human tissues for surgical applications has driven the market to identify alternatives, including polymeric and biologic materials. Animal tissue, particularly pig, is closing the gap in the critical shortage of human tissue. Current polymeric and conventional biologics exhibit a high degree of complications, in part due to the lack of adequate integration with the surrounding tissues. Sarcio has developed a superior porcine biologic material that addresses the integration deficiencies of polymeric and conventional biologics. Our material is prepared from pigs carrying a single gene knockout resulting in highly integration-competent decellularized tissues. Sarcio’s decellularized tissues are prepared using routine manufacturing methods and are demonstrably superior to conventional polymeric and biological scaffolds. Sarcio’s first planned application will be for hernia repair, a procedure that is performed up to 1 million times annually in the United States.
Modulation of MAP Kinase Phosphatases in Targeting Liver Disease. A novel platform for allosteric targeting of MAP kinase phosphatases to achieve nodal regulation of signaling pathways that can be leveraged for therapeutic purposes.
About half of treated cancer patients receive platinum-based drugs (eg. cisplatin, carboplatin) alone or in co-administration with other anticancer agents. Despite their efficacy, their use is limited by toxic side effects and inherent or acquired resistance to platinum-based drugs by tumor cells. To address this challenge, a Cornell team lead by Prof. Justin Wilson have developed rhenium-based chemotherapeutics for treatment of platinum-resistant cancers.
Ventilator Associated Pneumonia (VAP) is viewed as an inevitable consequence of long-term ventilator support rather than a preventable infection. In fact, VAP develops in 1 out of 3 intubated patients in intermediate care units. Along with the high prevalence, VAP has an average mortality rate of almost 50%. As a result, hospitals utilize procedural steps to prevent VAP in patients (such as head elevation and maintaining oral hygiene), but these actions fail to adequately prevent the root cause of VAP which is that current endotracheal (ET) tubes, or breathing tubes, do not create a long-term and effective seal in the trachea to prevent bacteria from entering the lungs. These tubes fail to create a proper seal because they employ an inflatable cuff that (1) deflates over time, (2) does not maintain consistent contact with the airway surface, and (3) is susceptible to shifting position with every patient movement. These design flaws allow harmful bacteria to pass the cuff and enter the lungs of patients.
Utilizes a lightweight algorithm and machine learning collected for 8 variables during the first 48 hours of hospitalization to predict the risk of 6-month mortality. Researchers at the University of Minnesota have developed a lightweight algorithm using machine learning for predicting the risk of 6-month mortality at the time of hospital admission. Using just 8 different variables collected during the first 48 hours of hospitalization, this algorithm predicted death within 6-months with an AUC of 0.92. The discriminative ability of this algorithm has been shown to be significantly better than historical estimates of clinician performance. This algorithm can be a critical tool in supporting clinical decision-making at admission and in evaluating suitable options such as transfer to tertiary referral center, serious illness care-conversations in high-risk patients, patient/family counseling, and palliative care utilization.
ChromaTiR (color through total internal reflection) is developing a technology to create color-shifting effects in a broad range of materials that is more cost-effective and safer. They are working to advance their patent-pending technology, which allows the use of a low-cost, simplified and more customizable method to generate vibrant, iridescent coatings in which no nanoparticles and no metal films are used. ChromaTiR offers customizable color shifting special effect coatings and pigments with tunable color profiles and large angular separation between colors.
Stork AI is leveraging its strong foundations in reproductive medicine, big data, and artificial intelligence to create next-generation fertility products that ultimately help people have babies. It is commercializing a decision assessment tool comprised of patent-pending, AI-based software (“STORK”) that reliably assesses embryo (blastocyst) quality. STORK was developed using a proprietary, multi-focal embryo image dataset from Weill Cornell’s Center for Reproductive Medicine. STORK can also predict genetic defects such as aneuploidy, which involves an abnormal number of chromosomes in the embryo.
The Future of Performance Fabrics IS Thermoregulation. What is Revolutionary here? In the sixties, waterproof-breathable membranes forever changed how we think about rainwear. In the nineties, we learned that polyester was superior to cotton in athletic wear, spawning a new age of fitness apparel. The next BIG THING will be THERMOREGULATORY materials – and they’ll revolutionize the industry.
The cellular industry has begun a transition toward open, programmable, and cloud-native architectures to reduce cost and address major management challenges. This transition (like the telecom migration to SDN) creates a significant new business opportunity for a flexible automated management system. zTouch Networks leverages years of research and development to provide the industry’s first data-driven, intelligent and autonomous network operating system to power this industry upgrade. The zTouch has extensive relationships with key industry partners and manages the world’s largest RF emulator, Colosseum (a $30M+ resource) and the testbeds in the NSF Platforms for Advanced Wireless Research (a $100M program). zTouch has an aggressive plan to pilot its platform in the next 18 months and is looking for partners and investors in this effort. It is looking to raise $5M to accelerate its pilot and add world-class leaders to run and grow the business.
geCKo Materials provides volume manufacturing for a bio-inspired, energy saving, reusable, multi-purpose, industrial and consumer adhesive. The mechanical adhesive is composed of directional, microscopic inclined features with a tapered geometry. geCKo’s unique IP is in the manufacturing method, introduced by Dr. Capella Kerst in her PhD at Stanford and protected by pending patents. Tested in the lab and in use with customers, a 1 square inch adhesive is capable of supporting 15 lbs of weight in shear with no attachment nor detachment force needed. The geCKo Opposing Force scales with area and can be purchased at any area. Integrating onto your robot grippers is simple, just a peel and stick. We can offer integration assistance and expertise for simple, quick and easy integration.
Smell loss is an early indicator of infectious and neurodegenerative disorders. In COVID-19, for example, objective smell loss may occur in >90% of patients. Though molecular (PCR) tests are effective in diagnosing SARS-CoV-2 infection, with moderate sensitivity and high specificity, they typically are costly (>$50), with long turnaround times (up to 5-7 days) and have not been as effective in controlling asymptomatic spread. The Aromha Smell Test complements molecular tests with high sensitivity and negative predictive value and can be scaled quickly to provide an important new tool to prevent community spread of COVID, with an at-home, non-invasive, safe, and cost-effective screening test that provides instantaneous results. This platform technology, developed based on 20 years of olfactory research at Harvard, can also be utilized to provide an early signal and improve care in critical neurodegenerative diseases such as Alzheimer's, Parkinson's Disease, and Traumatic Brain Injury.
ClaraSim Systems, Inc. has developed a computer simulated environment in which surgeons can perform surgery on virtual bone using virtual instruments. By combining patient-specific data with a powerful simulation engine, we are able to create 3-D patient models that can be explored and modified in real-time with virtual surgical tools providing both haptic and visual feedback. Our system enhances the surgeon's ability to perform skilled surgery by enabling them to rehearse drilling through accurate representations of the patient's bony and fragile structures. The anatomical insight gained from interacting with the simulation provides guidance during actual surgery leading to better outcomes. While the system enables preoperative rehearsal, it is also used as a teaching tool, giving trainees the opportunity to experience many different cases in a safe and efficient setting. The technological and clinical capabilities of the product stem from over 30 person-years of research conducted by the company founders.
Mucosinix has a new class of antibiotics which have not been shown to trigger resistance in MRSA culture. This new antibiotic class shows promise as a treatment for multidrug resistant microbes.
Millions of people all over the world face challenges with alcohol. One of the more traditional solutions people first consider is Alcoholics Anonymous. Through market research, we have learned that more and more non-traditional solutions are being sought out to supplement the recovery journey and we, at Milo Sensors, believe we can provide an option for the supervised or self-monitoring of alcohol consumption. Unlike other existing alcohol monitoring tools such as ankle bracelets, ION™ is designed for the wearer first, with discretion, comfort, and usability at the forefront. Common industries that benefit from similar monitoring devices, such as the criminal justice system or family law, seem to follow only after the recovery support network has failed and act as a punitive measure. In contrast, we aim to help anyone who seeks to improve their general wellness by focusing on their relationship with alcohol and then help rebuild trust with surrounding family members and supporters.